JPH10330286A5 - - Google Patents

Info

Publication number
JPH10330286A5
JPH10330286A5 JP1998088331A JP8833198A JPH10330286A5 JP H10330286 A5 JPH10330286 A5 JP H10330286A5 JP 1998088331 A JP1998088331 A JP 1998088331A JP 8833198 A JP8833198 A JP 8833198A JP H10330286 A5 JPH10330286 A5 JP H10330286A5
Authority
JP
Japan
Prior art keywords
abnormal
receptor
substance
disease caused
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP1998088331A
Other languages
Japanese (ja)
Other versions
JPH10330286A (en
Filing date
Publication date
Application filed filed Critical
Priority to JP10088331A priority Critical patent/JPH10330286A/en
Priority claimed from JP10088331A external-priority patent/JPH10330286A/en
Publication of JPH10330286A publication Critical patent/JPH10330286A/en
Publication of JPH10330286A5 publication Critical patent/JPH10330286A5/ja
Abandoned legal-status Critical Current

Links

Claims (33)

異常遺伝子産物作動物質を含有してなる、該産物に起因する疾患の予防・治療剤。A preventive/therapeutic agent for a disease caused by an abnormal gene product, comprising an agonist of said product. 異常遺伝子産物が、異常受容体、異常チャンネル、異常トランスポーターまたは異常酵素である請求項１記載の予防・治療剤。2. The preventive or therapeutic agent according to claim 1, wherein the abnormal gene product is an abnormal receptor, an abnormal channel, an abnormal transporter or an abnormal enzyme. 異常受容体作動物質を含有してなる、異常受容体に起因する疾患の予防・治療剤である請求項１記載の予防・治療剤。2. The preventive and therapeutic agent according to claim 1, which is a preventive and therapeutic agent for diseases caused by abnormal receptors, comprising an abnormal receptor agonist. 異常受容体に起因する疾患が、異常受容体を有する細胞の伝達系が実質的に低下することに起因する疾患である請求項３記載の予防・治療剤。4. The preventive and/or therapeutic agent according to claim 3, wherein the disease caused by an abnormal receptor is a disease caused by a substantial decrease in the signaling system of cells having the abnormal receptor. 異常受容体に起因する疾患が、異常受容体を有する細胞の伝達系を天然リガンドが実質的に作動しないことに起因する疾患である請求項３記載の予防・治療剤。4. The preventive and therapeutic agent according to claim 3, wherein the disease caused by an abnormal receptor is a disease caused by the natural ligand not substantially functioning in the transduction system of a cell having the abnormal receptor. 異常受容体に起因する疾患が、天然リガンドの異常受容体に対する親和性が実質的に低下することに起因する疾患である請求項３記載の予防・治療剤。4. The preventive and/or therapeutic agent according to claim 3, wherein the disease caused by the abnormal receptor is a disease caused by a substantial decrease in the affinity of a natural ligand for the abnormal receptor. 伝達系が、天然リガンドと受容体との結合により生じる応答物質の細胞内濃度変化に基づく伝達系である請求項５記載の予防・治療剤。6. The preventive and/or therapeutic agent according to claim 5, wherein the transduction system is a transduction system based on a change in the intracellular concentration of a response substance caused by binding between a natural ligand and a receptor. 応答物質がｃＡＭＰ、イノシトールリン酸またはカルシウムイオンである請求項７記載の予防・治療剤。8. The preventive or therapeutic agent according to claim 7, wherein the responsive substance is cAMP, inositol phosphate, or calcium ion. 異常受容体作動物質が、正常受容体を作動する物質である請求項３記載の予防・治療剤。4. The preventive and/or therapeutic agent according to claim 3, wherein the abnormal receptor agonist is a substance that agonizes a normal receptor. 異常受容体作動物質が、正常受容体を作動しない物質である請求項３記載の予防・治療剤。4. The preventive and/or therapeutic agent according to claim 3, wherein the abnormal receptor agonist is a substance that does not agonize a normal receptor. 異常遺伝子産物に起因する疾患の治療のための、該産物作動物質の用途。Use of an agonist of an abnormal gene product for the treatment of a disease caused by the product. 異常遺伝子産物が、異常受容体である請求項１０記載の用途。The use according to claim 10, wherein the abnormal gene product is an abnormal receptor. 異常遺伝子産物と被検物質とを接触させ、該産物に対する該物質の作動性を検定することを特徴とする、異常遺伝子産物作動物質のスクリーニング方法。A method for screening for a substance that acts on an abnormal gene product, which comprises contacting the abnormal gene product with a test substance and assaying the activity of the substance on the product. 異常遺伝子産物が、異常受容体である請求項１３記載のスクリーニング方法。The screening method according to claim 13, wherein the abnormal gene product is an abnormal receptor. 異常遺伝子産物と被検物質とを接触させ、該産物に対する該物質の作動性を検定することを特徴とする、異常遺伝子産物に起因する疾患の治療のための物質のスクリーニング方法。A method for screening a substance for treating a disease caused by an abnormal gene product, which comprises contacting an abnormal gene product with a test substance and assaying the activity of said substance on said product. 異常受容体と被検物質とを接触させ、異常受容体に対する該物質の作動性を検定することを特徴とする、異常受容体に起因する疾患に罹患した哺乳動物の異常受容体を有する細胞の伝達系を実質的に作動させるための薬物のスクリーニング方法。A method for screening drugs for substantially activating the transduction system of cells having abnormal receptors in mammals suffering from diseases caused by abnormal receptors, which comprises contacting an abnormal receptor with a test substance and examining the activity of the substance on the abnormal receptor. 異常受容体が、異常受容体をコードする遺伝子を細胞で発現させることにより調製された異常受容体である請求項１６記載のスクリーニング方法。17. The screening method according to claim 16, wherein the abnormal receptor is an abnormal receptor prepared by expressing a gene encoding the abnormal receptor in a cell. 異常受容体をコードする遺伝子が、異常受容体に起因する疾患に罹患した哺乳動物の細胞から調製された遺伝子と、異常受容体を保持しない同種の哺乳動物の細胞から調製された遺伝子とを比較解析することにより特定された異常受容体をコードする遺伝子である請求項１７記載のスクリーニング方法。The screening method of claim 17, wherein the gene encoding the abnormal receptor is a gene encoding an abnormal receptor identified by comparative analysis of a gene prepared from cells of a mammal suffering from a disease caused by the abnormal receptor with a gene prepared from cells of the same species of mammal that does not possess the abnormal receptor. 異常遺伝子産物と被検物質とを接触させ、該産物に対する該物質の作動性を検定し、異常遺伝子産物を実質的に作動すると判定される薬物を調製することを特徴とする、異常遺伝子産物に起因する疾患の治療のための薬物を調製する方法。A method for preparing a drug for treating a disease caused by an abnormal gene product, comprising contacting an abnormal gene product with a test substance, assaying the activity of the substance on the product, and preparing a drug that is determined to substantially activate the abnormal gene product. 異常受容体と被検物質とを接触させ、異常受容体に対する該物質の作動性を検定し、異常受容体を有する細胞の伝達系を実質的に作動すると判定される物質を調製することを特徴とする、異常受容体に起因する疾患の治療のための物質を調製する方法。A method for preparing a substance for treating a disease caused by an abnormal receptor, comprising contacting an abnormal receptor with a test substance, examining the activity of the substance on the abnormal receptor, and preparing a substance that is determined to substantially activate the transduction system of a cell having the abnormal receptor. 異常受容体が、異常受容体をコードする遺伝子を細胞で発現させることにより調製された異常受容体である請求項２０記載の方法。21. The method of claim 20, wherein the aberrant receptor is an aberrant receptor prepared by expressing a gene encoding the aberrant receptor in a cell. 異常受容体をコードする遺伝子が、異常受容体に起因する疾患に罹患した哺乳動物の細胞から調製された遺伝子と、異常受容体を保持しない同種の哺乳動物の細胞から調製された遺伝子とを比較解析することにより特定された異常受容体をコードする遺伝子である請求項２１記載の方法。The method of claim 21, wherein the gene encoding the abnormal receptor is a gene encoding an abnormal receptor identified by comparative analysis of genes prepared from cells of a mammal suffering from a disease caused by the abnormal receptor with genes prepared from cells of the same species of mammal that does not possess the abnormal receptor. 異常遺伝子産物をコードする遺伝子を細胞で発現させて得られる異常遺伝子産物の、該産物に起因する疾患の治療のための物質をスクリーニングするための用途。The use of abnormal gene products obtained by expressing genes encoding such products in cells to screen for substances for treating diseases caused by such products. 異常遺伝子産物が、異常受容体である請求項２３記載の用途。24. The use according to claim 23, wherein the abnormal gene product is an abnormal receptor. 異常遺伝子産物をコードする遺伝子を細胞で発現させて得られる異常遺伝子産物の、該産物作動物質をスクリーニングするための用途。The use of abnormal gene products obtained by expressing a gene encoding the abnormal gene product in a cell to screen for substances that act on the product. 異常遺伝子産物が、異常受容体である請求項２５記載の用途。26. The use according to claim 25, wherein the abnormal gene product is an abnormal receptor. 受容体の構造遺伝子が生体内で変異した結果、天然リガンドの親和性が実質的に変化した異常受容体を作動しうる物質のスクリーニング方法であって、（ａ）異常受容体をコードする遺伝子を細胞で発現させる工程；（ｂ）工程（ａ）で得られる異常受容体に被験物質を接触させる工程；および（ｃ）異常受容体に対する該物質の作動性を検定する工程を含有することを特徴とする、スクリーニング方法。A screening method for a substance that can activate an abnormal receptor whose affinity for a natural ligand has substantially changed as a result of mutation of the receptor's structural gene in the body, characterized in that it comprises: (a) a step of expressing a gene encoding the abnormal receptor in a cell; (b) a step of contacting a test substance with the abnormal receptor obtained in step (a); and (c) a step of assaying the activating ability of the substance on the abnormal receptor. 異常受容体が、天然リガンドの親和性の実質的な変化に起因して疾患を引き起こす受容体である請求項２７記載の方法。28. The method of claim 27, wherein the abnormal receptor is a receptor that causes disease due to a substantial change in the affinity of its natural ligand. さらに、（ｄ）異常受容体のアゴニストまたはアンタゴニストを選択する工程を含む、請求項２７または２８記載の方法。The method of claim 27 or 28, further comprising the step of (d) selecting an agonist or antagonist of the abnormal receptor. 異常受容体に起因する疾患を罹患した哺乳動物において、異常受容体を有する細胞の伝達系を実質的に作動させるための薬物のスクリーニング方法である請求項２７記載の方法。The method according to claim 27, which is a method for screening for a drug that substantially activates the transduction system of a cell having an abnormal receptor in a mammal suffering from a disease caused by the abnormal receptor. 伝達系が、天然リガンドと受容体との結合により生じる応答物質の細胞内濃度変化に基づく伝達系である請求項２７記載の方法。The method according to claim 27, wherein the transduction system is a transduction system based on a change in the intracellular concentration of a response substance caused by binding between a natural ligand and a receptor. 応答物質がｃＡＭＰ、イノシトールリン酸またはカルシウムイオンである請求項３１記載の方法。32. The method of claim 31, wherein the response substance is cAMP, inositol phosphate, or calcium ion. 異常受容体をコードする遺伝子が、異常受容体に起因する疾患に罹患した哺乳動物の細胞から調製された遺伝子と、異常受容体を保持しない同種の哺乳動物の細胞から調製された遺伝子とを比較解析することにより特定された異常受容体をコードする遺伝子である請求項２７記載の方法。The method of claim 27, wherein the gene encoding the abnormal receptor is a gene encoding an abnormal receptor identified by comparative analysis of genes prepared from cells of a mammal suffering from a disease caused by the abnormal receptor with genes prepared from cells of the same species of mammal that does not possess the abnormal receptor.
JP10088331A 1997-04-02 1998-04-01 Use and screening of abnormal gene product agent Abandoned JPH10330286A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP10088331A JPH10330286A (en) 1997-04-02 1998-04-01 Use and screening of abnormal gene product agent

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP8375897 1997-04-02
JP9-83758 1997-04-02
JP10088331A JPH10330286A (en) 1997-04-02 1998-04-01 Use and screening of abnormal gene product agent

Publications (2)

Publication Number Publication Date
JPH10330286A JPH10330286A (en) 1998-12-15
JPH10330286A5 true JPH10330286A5 (en) 2005-06-09

Family

ID=26424794

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10088331A Abandoned JPH10330286A (en) 1997-04-02 1998-04-01 Use and screening of abnormal gene product agent

Country Status (1)

Country Link
JP (1) JPH10330286A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2381226A1 (en) * 1999-08-05 2001-02-15 Takeda Chemical Industries, Ltd. Method of recording gene analysis data

Similar Documents

Publication Publication Date Title
Ademuwagun et al. Voltage gated sodium channel genes in epilepsy: mutations, functional studies, and treatment dimensions
Beeson et al. Mutations affecting muscle nicotinic acetylcholine receptors and their role in congenital myasthenic syndromes
Gault et al. Comparison of polymorphisms in the α7 nicotinic receptor gene and its partial duplication in schizophrenic and control subjects
Goldman et al. Pertussis toxin inhibition of chemotactic factor-induced calcium mobilization and function in human polymorphonuclear leukocytes.
Honda et al. The coxsackievirus-adenovirus receptor protein as a cell adhesion molecule in the developing mouse brain
Amenta et al. Identification of dopamine plasma membrane and vesicular transporters in human peripheral blood lymphocytes
Lotocki et al. Tumor necrosis factor receptor 1 and its signaling intermediates are recruited to lipid rafts in the traumatized brain
Pillai et al. A coding polymorphism in the CYSLT2 receptor with reduced affinity to LTD4 is associated with asthma
AU2003218345A1 (en) Treatment of amyotrophic lateral sclerosis with nimesulide
Noubade et al. von-Willebrand factor influences blood brain barrier permeability and brain inflammation in experimental allergic encephalomyelitis
JP2003506050A (en) Modulatory binding sites of potassium channels for screening
Whiteaker et al. Pharmacological and null mutation approaches reveal nicotinic receptor diversity
Jones et al. The Gβγ dimer as a novel source of selectivity in G-protein signaling: GGL-ing at convention
Rebelo et al. A CADM3 variant causes Charcot-Marie-Tooth disease with marked upper limb involvement
CN1184254A (en) Modulation of opioid receptor function
Tohda et al. Molecular pathopharmacology of 5-HT2C receptors and the RNA editing in the brain
Allan et al. Gamma‐Aminobutyric Acid‐Activated Chloride Channels in Rats Selectively Bred for Differential Acute Sensitivity to Alcohol
Remmers et al. Activation of G protein by opioid receptors: role of receptor number and G-protein concentration
JPH10330286A5 (en)
Mizoguchi et al. Lack of μ-opioid receptor-mediated G-protein activation in the spinal cord of mice lacking Exon 1 or Exons 2 and 3 of the MOR-1 gene
JP2005508879A (en) Novel class II cytokine receptors and uses thereof
Poulopoulou et al. Glutamate levels and activity of the T cell voltage‐gated potassium Kv1. 3 channel in patients with systemic lupus erythematosus
Åkesson et al. Ionotropic glutamate receptor expression in human spinal cord during first trimester development
CA2263798A1 (en) G-coupled receptor showing selective affinity for atp
Karege et al. The effect of clinical outcome on platelet G proteins of major depressed patients